4 articles
A comprehensive review maps every major in vitro aging model—from Hayflick's fibroblasts to iPSCs—and the interventions that reverse cellular aging.
Master the cutting-edge molecular targets, clinical trial data, and emerging therapeutic strategies aimed at reversing ECM aging — from senolytic combinations to biomaterial scaffolds and epigenetic reprogramming.
Activating three Yamanaka factors — OCT4, SOX2, and KLF4 — appears to reverse epigenetic aging in human eye cells, marking a milestone in rejuvenation medicine.
Boston biotech secures major funding to complete Phase 1 trials of ER-100, a therapy targeting aging through epigenetic reprogramming.
